Literature DB >> 17463109

Chromium and cobalt ion release following the Durom high carbon content, forged metal-on-metal surface replacement of the hip.

P-A Vendittoli1, S Mottard, A G Roy, C Dupont, M Lavigne.   

Abstract

We evaluated the concentrations of chromium and cobalt ions in blood after metal-on-metal surface replacement arthroplasty using a wrought-forged, high carbon content chromium-cobalt alloy implant in 64 patients. At one year, mean whole blood ion levels were 1.61 microg/L (0.4 to 5.5) for chromium and 0.67 microg/L (0.23 to 2.09) for cobalt. The pre-operative ion levels, component size, female gender and the inclination of the acetabular component were inversely proportional to the values of chromium and/or cobalt ions at one year postoperatively. Other factors, such as age and level of activity, did not correlate with the levels of metal ions. We found that the levels of the ions in the serum were 1.39 and 1.37 times higher for chromium and cobalt respectively than those in the whole blood. The levels of metal ions obtained may be specific to the hip resurfacing implant and reflect its manufacturing process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17463109     DOI: 10.1302/0301-620X.89B4.18054

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  37 in total

1.  Surgical variables influence metal ion levels after hip resurfacing.

Authors:  Nicholas M Desy; Stephane G Bergeron; Alain Petit; Olga L Huk; John Antoniou
Journal:  Clin Orthop Relat Res       Date:  2011-06       Impact factor: 4.176

2.  Failure of the Durom Metasul acetabular component.

Authors:  William T Long; Manish Dastane; Michael J Harris; Zhinian Wan; Lawrence D Dorr
Journal:  Clin Orthop Relat Res       Date:  2009-09-02       Impact factor: 4.176

3.  Biomonitoring method for the analysis of chromium and cobalt in human whole blood using inductively coupled plasma - kinetic energy discrimination - mass spectrometry (ICP-KED-MS).

Authors:  Joaudimir Castro Georgi; Yuliya L Sommer; Cynthia D Ward; Po-Yung Cheng; Robert L Jones; Kathleen L Caldwell
Journal:  Anal Methods       Date:  2017-04-19       Impact factor: 2.896

4.  Do ion levels in hip resurfacing differ from metal-on-metal THA at midterm?

Authors:  A Moroni; L Savarino; M Hoque; M Cadossi; N Baldini
Journal:  Clin Orthop Relat Res       Date:  2010-06-11       Impact factor: 4.176

5.  What are the risks accompanying the reduced wear benefit of low-clearance hip resurfacing?

Authors:  Joseph Daniel; Hena Ziaee; Amir Kamali; Chandra Pradhan; Derek McMinn
Journal:  Clin Orthop Relat Res       Date:  2012-07-24       Impact factor: 4.176

6.  Insufficient acetabular version increases blood metal ion levels after metal-on-metal hip resurfacing.

Authors:  Alister J Hart; John A Skinner; Johann Henckel; Barry Sampson; Fabiana Gordon
Journal:  Clin Orthop Relat Res       Date:  2011-06-09       Impact factor: 4.176

7.  2008 John Charnley award: metal ion levels after metal-on-metal total hip arthroplasty: a randomized trial.

Authors:  C Anderson Engh; Steven J MacDonald; Supatra Sritulanondha; Abigail Thompson; Douglas Naudie; Charles A Engh
Journal:  Clin Orthop Relat Res       Date:  2008-10-15       Impact factor: 4.176

8.  Delayed sciatic nerve palsy following resurfacing hip arthroplasty caused by metal debris.

Authors:  Babar Kayani; Jeeshan Rahman; Sammy A Hanna; Stephen R Cannon; William J Aston; Jonathan Miles
Journal:  BMJ Case Rep       Date:  2012-11-14

9.  The John Charnley Award: Metal-on-metal hip resurfacing versus large-diameter head metal-on-metal total hip arthroplasty: a randomized clinical trial.

Authors:  Donald S Garbuz; Michael Tanzer; Nelson V Greidanus; Bassam A Masri; Clive P Duncan
Journal:  Clin Orthop Relat Res       Date:  2009-08-21       Impact factor: 4.176

10.  Accuracy of computer-assisted navigation for femoral head resurfacing decreases in hips with abnormal anatomy.

Authors:  Rocco P Pitto; Sharif Malak; Iain A Anderson
Journal:  Clin Orthop Relat Res       Date:  2009-05-07       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.